VGCC Antibody Testing in Small Cell Lung Cancer: Assays, Interpretation, and the Seronegative Patient

Dr. Sen explains VGCC antibody testing in depth. The gold-standard assay is radioimmunoassay using a radioactive tracer; cell-based and ELISA-style assays are increasingly available. P/Q-type VGCC antibodies are positive in approximately 85% to 95% of true LEMS cases; N-type co-occurs in approximately one-third to 40% of cases but is not independently diagnostic. A common interpretive pitfall is over-relying on titer level: antibody titers do not reliably correlate with symptom severity. A mildly elevated result in a patient with a fitting clinical picture, with weakness, reflex changes, autonomic symptoms, should not be dismissed. In contrast, 5% to 15% of true LEMS patients test seronegative, so a negative result does not exclude the diagnosis when clinical and electrophysiologic findings are consistent. Practical guidance includes knowing which assay your institution uses (and whether it tests both P/Q and N types), interpreting results against laboratory-specific rather than generic reference ranges, and treating the full clinical picture as the decisive framework rather than the antibody result in isolation.